Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | RAF1 | P04049 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | BTK | Q06187 | 4/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | BLK | P51451 | 1/20 | 0.37 |
| ▸ | BMX | P51813 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484367 | 0.86 | EGFR (0.51) | JAK3EGFRBTKJAK2BLK | |
| SCHEMBL21515873 | 0.80 | RAF1 (0.37) | JAK3BRAFRAF1JAK2JAK1 | |
| SCHEMBL21484328 | 0.79 | EGFR (0.47) | JAK3BRAFRAF1EGFRBTK | |
| SCHEMBL29538509 | 0.78 | JAK3 (0.46) | JAK3EGFRBTKJAK2BLK | |
| SCHEMBL21484313 | 0.77 | MEN1 (0.38) | JAK3JAK2JAK1PTK2 | |
| SCHEMBL21515827 | 0.76 | EGFR (0.52) | JAK3EGFRBTKJAK2BLK | |
| SCHEMBL21758128 | 0.75 | EGFR (0.54) | JAK3EGFRBTKJAK2BLK | |
| SCHEMBL21758097 | 0.74 | EGFR (0.39) | JAK3BRAFRAF1EGFRBTK | |
| SCHEMBL21484354 | 0.74 | TLR7 (0.34) | JAK3BTKJAK2JAK1 | |
| SCHEMBL21515951 | 0.73 | EGFR (0.49) | JAK3EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BTK, SYK, ITK | JAK3 33/4885BRAF 25/4885RAF1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.